Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
is a biopharmaceutical company that focuses on development and
commercialization of treatments for infectious diseases. The company has
four potential drug candidates in its pipeline in phases 1 and 2 of
clinical trials. The stock has been bullish since June this year when
the company announced it has begun administrating doses of ACH 3422 to
treat patients with genotype 1 chronic Hepatitis C viral infection
(HCV). The stock of the company jumped 170% after the announcement and
has continued to surge as. ACH 3422 is currently undergoing phase 1
clinical trials, and the trial results are expected to be reported by
the end of the year.
four drug candidates are all part of its proprietary hepatitis C
inhibitor program. The proteins of HCV are structured in a specific
order: nonstructural protein 2 (NS2)–NS3–NS4A–NS4B–NS5A–NS5B–C-terminal.
Each of the inhibitors developed by Achillion is designed to target a
different protein in the structure of the virus.
3422, for example, is an NS5B enzyme inhibitor, and if the proof of
concept will be successful, ACH 3422 will be the first all-oral compound
designed to inhibit hepatitis C NS5B. Other investigational compounds
include ACH-2684 that is undergoing phase 1 clinical trials, ACH 3102 and Sovaprevir which are currently in phase 2 clinical trials.